60439-46-5 Usage
Uses
Used in Pharmaceutical Industry:
3-Morpholinopropyl=3,4,5-trimethoxybenzoate is used as a pharmaceutical compound for its potential to interact with biological targets due to its unique structure. This interaction may contribute to the development of new drugs or therapies.
Used in Organic Synthesis:
3-Morpholinopropyl=3,4,5-trimethoxybenzoate is used as a reagent in organic synthesis, where it can be employed to create new compounds with specific properties or functions.
Used in Research Settings:
3-Morpholinopropyl=3,4,5-trimethoxybenzoate is used as a building block in research settings to investigate its potential biological activities and explore its applications in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 60439-46-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,0,4,3 and 9 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 60439-46:
(7*6)+(6*0)+(5*4)+(4*3)+(3*9)+(2*4)+(1*6)=115
115 % 10 = 5
So 60439-46-5 is a valid CAS Registry Number.
InChI:InChI=1/C17H25NO6/c1-20-14-11-13(12-15(21-2)16(14)22-3)17(19)24-8-4-5-18-6-9-23-10-7-18/h11-12H,4-10H2,1-3H3
60439-46-5Relevant academic research and scientific papers
Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2)
Playa, Hilaire,Lewis, Timothy A.,Ting, Amal,Suh, Byung-Chul,Muoz, Benito,Matuza, Robert,Passer, Brent J.,Schreiber, Stuart L.,Buolamwini, John K.
, p. 5801 - 5804 (2015/01/08)
As ENT inhibitors including dilazep have shown efficacy improving oHSV1 targeted oncolytic cancer therapy, a series of dilazep analogues was synthesized and biologically evaluated to examine both ENT1 and ENT2 inhibition. The central diamine core, alkyl chains, ester linkage and substituents on the phenyl ring were all varied. Compounds were screened against ENT1 and ENT2 using a radio-ligand cell-based assay. Dilazep and analogues with minor structural changes are potent and selective ENT1 inhibitors. No selective ENT2 inhibitors were found, although some analogues were more potent against ENT2 than the parent dilazep.
